- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
New CEO for Amplyx Pharmaceuticals
January 06, 2017
Ciara Kennedy
Amplyx Pharmaceuticals (San Diego, CA) has appointed Ciara Kennedy, Ph.D., to president and chief executive officer and Karen Joy Shaw, Ph.D., to chief scientific officer (CSO). The company's former president and CEO, Mike Grey, has assumed the role of executive chairman of the Amplyx Board of Directors. Dr. Kennedy joined Amplyx as chief operating officer in October 2015. Prior to that, she served as vice president and cholestatic liver disease program head at Shire Pharmaceuticals, and as COO of Lumena Pharmaceuticals.
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.
Plan Ahead: Mastering Your AI Budget for 2025 Success
October 9th 2024Generative AI is just one part of the artificial intelligence and machine learning that is being used by life science organizations, emerging as a major area of interest and an area in which costs and ROI are still largely unknown.
